

 <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p>				<i>Complete if Known</i>	
				Application Number	10/553,317
				Filing Date	September 26, 2006
				First Named Inventor	RUDOLPH
				Group Art Unit	1654
				Examiner Name	
				Confirmation No.	1807
Sheet	1	of	1	Attorney Docket Number	2697-120

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
/R.N./	1	D'AGOSTINI et al., "Efficacy of Combination Therapy with Amantadine, Thymosin $\alpha$ 1 and $\alpha$ / $\beta$ Interferon in Mice Infected with Influenza A Virus" <i>Int. J. Immunopharmac</i> , Vol. 13, No 2, pp. 95-102, 1996	
Examiner Signature	/Ronald Niebauer/		Date Considered 12/13/2007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

